A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues - Takeaways - MDSpire

A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues

  • By

  • Li Zhong

  • Wenxuan Cao

  • Xinyu Liu

  • Tiancai Wen

  • Jing Yan

  • March 17, 2026

  • 0 min

Share

  • 1

    The study analyzed 102,953 FAERS reports to evaluate visual impairment adverse events linked to insulin degludec, detemir, and glargine.

  • 2

    Insulin glargine showed the strongest association with visual impairment AEs, particularly diabetic glaucoma, while degludec was linked to diabetic retinopathy.

  • 3

    Over 60% of visual impairment reports involved female patients, and 93% of reports originated from the United States.

  • 4

    Multivariate regression suggested higher body weight might be a protective factor against visual impairment, though findings may be confounded.

  • 5

    The study highlights the need for individualized ophthalmic monitoring during the early phase of initiating basal insulin therapy in diabetic patients.

Original Source(s)

A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues

  • by Li Zhong, Wenxuan Cao, Xinyu Liu, Tiancai Wen, Jing Yan

  • March 17, 2026

Related Content

Does Metabolic and Bariatric Surgery Reduce the Risk of Developing Parkinson’s Disease: A Propensity Score Matching Analysis Using Data from the National Inpatient Sample

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Steroid Strategies in Diabetic Macular Edema